Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tetrodotoxin - Dogwood therapeutics

Next Previous
X
Search
Drug Profile

Tetrodotoxin - Dogwood therapeutics

Alternative Names: 9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin

Latest Information Update: 07 Mar 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Medical University; WEX Pharmaceuticals
  • Class Anaesthetics; Analgesics; Antiarrhythmics; Drug withdrawal therapies; Quinazolines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Neuropathic pain; Pain; Peripheral nervous system diseases
  • Suspended Opioid-related disorders
  • No development reported Anaesthesia

Most Recent Events

  • 20 Feb 2025 Wex Pharmaceuticals terminates a phase II trial in Peripheral nervous system diseases and Neuropathic pain (In adults, In the elderly) in USA (SC) due to lack of funding to continue the study (NCT05359133)
  • 21 Jan 2025 Dogwood Therapeutics plans a phase IIb HALT-CINP trial for Neuropathic pain (Chemotherapy-induced), in first quarter of 2025
  • 07 Oct 2024 Tetrodotoxin receives Fast Track designation for Neuropathic pain [Parenteral,Injection] (Chemotherapy-induced) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top